Kornimate/medical-research-clean huggingface dataset:
music therapy in acute leukemia patients with fatigue

Conditions: Acute Myeloid Leukemia; Fatigue

Summary: the objective of this study is to assess the efficacy of employing music therapy in alleviating fatigue and medical laboratory values among patients with acute myeloid leukemia.

the researchers will explain the study objectives and methods, obtain informed consent, and have participants sign the consent form before commencing the study. participants are randomly assigned to group a and group b. participants in group a undergo 30 minutes of self-selected music playback every day in addition to receiving standard therapy, while participants in group b only receive standard therapy. the entire study duration spans 21 days.

Eligibility criteria:
inclusion criteria: 1. diagnosed with acute myeloid leukemia by a clinical specialist. 2. patients undergoing chemotherapy for the first time. 3. aged 18 years or older, capable of communicating in mandarin or taiwanese. 4. normal hearing ability. 5. no history of psychiatric disorders and clear consciousness. 6. participants with no prior involvement in any intervention studies related to fatigue management. 7. demonstrates understanding of the research objectives, willingly participates in the study, and completes the informed consent form. 8. willing to cooperate with study procedures throughout the research period. exclusion criteria: 1. severe hearing impairment. 2. individuals with unstable vital signs or altered consciousness.

Keywords: aml music fatigue
early detection of cmp in patients with breast cancer using cardiac magnetic resonance

Conditions: Breast Cancer; Chemotherapy Induced Systolic Dysfunction

Summary: breast cancer is the most common cancers among women worldwide.although chemotherapy and surgery have greatly improved the survival rate, most types of chemotherapy have been reported to have varying degrees of cardiotoxicity. the investigators will focus on the cardiotoxicity of pyrotinib and apatinib which belong to the new tyrosine kinase inhibitors in respective chemotherapy among more subjects.

breast cancer is the most common cancers among women worldwide. although chemotherapy and surgery have greatly improved the survival rate, most types of chemotherapy have been reported to have varying degrees of cardiotoxicity. we have focused on the field of chemotherapy-related cardiomyopathy. using the unified magnetic resonance sequences and parameters, effect of chemotherapeutic drugs on the myocardium are studies. our team's previous pilot study has found that chemotherapy-related cardiomyopathy (cmp) may be predicted within one week after chemotherapy initiation. the specific intervention timing, and the sensitivity and specificity of the early screening indicators are to be explored. at the same time, in patients with human epidermalgrowth factor receptor-2-positive breast cancer, our team observed the change of blood pressure, exercise tolerance and myocardial structure, function and tissue characteristics in patients who used tyrosine kinase inhibitors (pyrotinib and apatinib). this is a supplement to the existing drug knowledge. we are planning to further explore whether it is related to the patient's pre-existing cardiovascular diseases, drug type, dose or dosing. there are no published data addressing the above two research areas. the overall goal is to explore the commonness and specificity of myocardial changes after chemotherapy in breast cancer patients and to predict the development of cmp through multimodality imaging and clinical indices. we aim to propose the cmp time window in respective chemotherapy among more subjects.

Eligibility criteria:
inclusion criteria: * age between 18-70 years old. * invasive breast cancer confirmed by pathology * left ventricular ejection fraction ≥ 50% * having not received any prior systemic anti-cancer therapy for advanced disease * an eastern cooperative oncology group（ecog） performance status 0-1 * providing written informed consent inclusion criteria for control group: * absence of known systemic diseases * normal examinations * age between 18-70 years old. * providing written informed consent exclusion criteria: * age \ 70 years old * documented coronary artery disease or prior angiography for coronary artery disease (\>50% stenosis). * patients with bilateral invasive breast cancers. * patients with metastasis of breast cancer confirmed by imaging or pathology * patients with standard metallic contraindications to cmr or an estimated glomerular filtration rate \< 30 ml/min/1.73 m2.

Keywords: chemotherapy-induced cardiomyopathy pyrotinib/apatinib cardiac magnetic resonance echocardiography
adjuvants with intrathecal bupivacaine for postoperative analgesia

Conditions: Postoperative Pain

Summary: the aim of this study is to compare the postoperative analgesic effect of intrathecal dexmedetomidine combined with bupivacaine and midazolam combined with bupivacaine in high tibial osteotomy.

with more than 80% of patients experiencing acute pain following surgical procedures, and half of them reporting inadequate pain therapy, the control and management of post-surgical pain remains one of the most challenging aims of modern anesthesia. adequate postoperative pain control is an important part of postoperative care treatment. world health organization, as well as international association for the study of pain, have emphasized its significance for patients well-being, and determined pain relief to be a human right and the occurrence of pain as fifth vital sign. local anesthetic, bupivacaine, is the most common agent used for spinal anesthesia but has relatively short duration of action. many adjuvants to local anesthetics have been used intrathecally to improve the quality of intraoperative analgesia and prolong it in the postoperative period. diverse classes of drugs such as opioids , epinephrine , neostigmine , magnesium , midazolam , ketamine , and clonidine have been added to intrathecal local anaesthetics in an attempt to prolong analgesia and reduce the incidence of adverse events. opioids are commonly added to local anaesthetics to produce spinal and epidural anesthesia. however, significant adverse effects such as, urinary retention, respiratory depression, hemodynamic instability, pruritus and occasionally severe nausea and vomiting, may limit their use . α2-adrenergic agonists are new neuraxial adjuvants being studied to improve the quality of subarachnoid blockade regarding both sensory and motor blockades. there are many studies supporting their efficacy as adjuvants individually. dexmedetomidine, a highly specific, potent, and selective α2-adrenergic agonist, provides stable hemodynamic conditions and good quality of intraoperative and prolonged postoperative analgesia with minimal side effects. discovery of benzodiazepine receptors in spinal cord in 1977 triggered the use of intrathecal midazolam for prolongation of spinal anesthesia.

Eligibility criteria:
inclusion criteria: * adult patients aged 18-60 years. * gender: both males and females. * scheduled patients for high tibial osteotomy under spinal anesthesia. * american society of anesthesiologists (asa) physical status: i and ii exclusion criteria: * patient refusal * allergy to the studied drugs. * patients with contraindications to spinal anesthesia. * patients with advanced decompensated cardiac, respiratory,renal or hepatic diseases * coagulopathy or thrombocytopenia * cns diseases as epilepsy, stroke or psychiatric illness.
edwards sapien-3 periprosthetic leakage evaluation versus medtronic corevalve in transfemoral aortic valve implantation

Conditions: Periprosthetic Aortic Valve Regurgitation After TAVI

Summary: transcatheter aortic valve replacement (tavr) is a good alternative treatment for patients with severe aortic valve stenosis with similar mid-term success rates as compared to surgery. periprosthetic aortic regurgitation (par) after tavr remains an important limitation of this technique. moderate to severe par occurs in 15-45% of the cases and it is an independent predictor of mortality after tavr. little is known about potential differences in severity of par among different types of aortic valve prosthesis. the current randomized study aims to evaluate potential differences between the edwards sapien bioprosthesis and the medtronic corevalve® system with main focus on par and additional focus on other clinical and imaging endpoints. primary objective of this study is to investigate the difference in the severity of par, measured with 3-dimensional transesophageal echocardiography (3dtee), between patients undergoing the implantation of the edwards sapien bioprosthesis versus patients receiving the medtronic corevalve® bioprosthesis. secondary objectives of this study include: investigating the value of different imaging modalities in evaluating periprosthetic regurgitation after tavr and studying the difference in clinical endpoints according to varc-2 definitions and quality of life after tavr between two available aortic valve prostheses.


Eligibility criteria:
inclusion criteria in order to be eligible to participate in this study, subjects must meet all of the following criteria: * patient is ≥18 years of age and diagnosed with severe symptomatic aortic stenosis, judged inoperable or at high surgical risk (euroscore \> 15% or other criteria that make surgery high risk by a consensus among cardiologists and cardiac surgeons in the heart team) and deemed eligible for transfemoral-tavi. * aortic annulus diameter ≥ 18 and ≤ 29 mm as assessed with msct. * no contraindications to study requirements such as mri or tee. exclusion criteria * patients unable or unwilling to give informed consent. * patients who are excluded from this study because of the size of their aortic annulus diameter.

Keywords: periprosthetic aortic valve regurgitation 3d transesophageal echocardiography cardiac mri
comparison of clarus and optos ultrawide field imaging systems for geographic atrophy

Conditions: Macular Degeneration, Age Related; Geographic Atrophy

Summary: the goal of this clinical trial is to compare measurements of geographic atrophy (ga) area between several types of imaging, in order to assess accuracy. the main question to answer is which imaging device provides measurements that are most similar to the standard of care device. participants will be patients of a retina doctor at university station eye clinic with geographic atrophy, and can expect to be in the study for 60-75 minutes.

this study is a single site pilot comparative imaging study in which enrolled participants will undergo dilated fundus exam as per standard of care. study images will be obtained using optos ultrawide field fundus autofluorescence (faf) and both blue and green ultrawide field faf with zeiss clarus. autofluorescence (af) imaging will also be performed on the spectralis as it is currently the gold standard. the goal will be to obtain all images in 60-75 minutes over one visit. images will be assessed, and area of geographic atrophy measured independently by two experienced readers.

Eligibility criteria:
inclusion criteria: * 50 years or older and may be either male or female and may be of any race * established diagnosis of ga due to amd * ga characteristics: ga area of between 1.25 mm² and 23 mm², with seventy percent of eyes having ga area ranging from 2.5 mm² to 17.5 mm². ga may be unifocal or multifocal. ga may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal ga. the presence of concurrent peripapillary atrophy will not exclude subjects from participation * willing to participate as evidenced by signing the written informed consent exclusion criteria: * unable to tolerate opthalmic imaging * presence of neovascular amd on oct as confirmed by an ophthalmologist * presence of significant media opacity preventing adequate retinal imaging * presence of concurrent retinal disease which may confound assessment
a study investigating the safety, tolerability, immunogenicity and pharmacokinetics of olamkicept in healthy persons

Conditions: Inflammatory Gastrointestinal Diseases

Summary: interleukin (il)-6 is a cytokine produced in response to infection and tissue damage. il-6 is believed to act as a key mediator in chronic inflammation and autoimmune diseases such as inflammatory bowel diseases. il-6 is known to be involved in at least two distinct signalling pathways, classical and trans-signalling. the hypothesis is that classical signalling by il-6 infers some beneficial effects (e.g. on gut barrier function), while excessive il-6 trans-signalling may have detrimental effects. olamkicept (fe 999301) has been shown in vitro to be a selective il-6 trans-signalling inhibitor, and administered at lower doses (600 mg every 2nd week for 12 weeks) it has proven to induce clinical improvement for patients with ulcerative colitis. the aim of this trial is to investigate safety, tolerability, immunogenicity and pharmacokinetics of olamkicept at higher doses (up to 2400 mg) to support the clinical development program. our hypothesis is that treatment with higher doses of olamkicept will result in greater clinical improvement for patients with inflammatory bowel diseases.


Eligibility criteria:
inclusion criteria: * men ≥18 and ≤45 years of age at screening * in good health, determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ecg), vital signs measurements, and clinical laboratory evaluations, as assessed by the investigator (or designee) at screening and on day -1 exclusion criteria: * history of clinically significant medical conditions including, but not limited to, diseases of the renal, hepatic, respiratory, gastrointestinal, cardiovascular, neurological, musculoskeletal, psychiatric, immunological, haematological, oncological, endocrine, and metabolic systems and allergic diseases (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
oncostatin m in ulcerative colitis patients

Conditions: Ulcerative Colitis

Summary: ulcerative colitis (uc) is a refractory disease characterized by symptoms such as diarrhea, bloody stools, and abdominal pain with repeated relapses and remissions.

evaluation of uc activity is important, and endoscopic evaluations of mucosal inflammation can facilitate subsequent prognostication. on the basis of these considerations, achievement of mucosal healing is important in inflammatory bowel disease (ibd), and evaluation of ibd using endoscopy is extremely important. however, endoscopic examinations are associated with problems such as physical burden to the patient, cost, and risk of complications. thus, to avoid the need for frequent endoscopy, noninvasive biomarkers that accurately reflect the endoscopic activity of uc have emerged, and fecal calprotectin (fc) and the fecal immunochemical occult blood test (fit) are being widely used in clinical practice.

Eligibility criteria:
inclusion criteria: * all patients aged \>18 years and \<80 years, of both gender who diagnosed to have uc and given the consent for participation in the study exclusion criteria: * 1- any patient with systemic inflammation as bronchial asthma. 2- history of cancer or tumor. 3- autoimmune disease such as rheumatoid arthritis and systemic lupus erythematous
helicobacter pylori immune thrombocytopenic purpura

Conditions: Immune Thrombocytopenic Purpura

Summary: we designed a study for evaluate the efficacy of helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenic purpura (itp) patients with moderate thrombocytopenia. if this eradication treatment is revealed effective on itp patients with more than 30x109/l of platelet, it would be valuable treatment especially for young itp patients with mild to moderate thrombocytopenia.

lansoprazole 30mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 7 days. (jeil pharm. co. ltd. will provide lansoprazole.) c13-ubt, at 4 weeks after onset of treatment, to determine eradication

Eligibility criteria:
inclusion criteria: * 20\~55 years old * persistent or chronic itp patients, defined by international working group ( persistent: between 3 to 12 months from diagnosis, chronic: lasting for more than 12 months) * 30x109/l ≤ platelet count ≤ 70x109/l * c13-urea breath test: positive * no previous itp treatment * no previous h. pylori eradication treatment * patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital exclusion criteria: * patients who have any cause of thrombocytopenia such as hiv, hcv infection, lymphoproliferative disease, liver disease, definite sle, drug, mds, leukemia * uncontrolled hypothyroidism or hyperthyroidism * acute active bleeding or infection * who taking anti-coagulant or aspirin * patients with penicillin allergy * patients with side effects of macrolide. * patients who taking mizolastine, terfenadine, cisapride, pimozide, astemizole, ergot alkaloid and its derivatives (ergotamine, dihydroergotamine), bepridil, or atazanavir * patients who have known allergy or severe side effect on study drugs * pregnant or lactating women * clinically relevant hepatic or renal disease (creatinine clearance ≤ 30ml/min) * patients who cannot understand informed consent or express his/her condition

Keywords: itp
construction of an ultrasound profile and a mammographic profile corresponding to the different molecular subtypes of brest cancer. a retrospective study

Conditions: Breast Cancer

Summary: profils is a retrospective, exploratory study on data collected in 203 breast cancer cases diagnosed during a national screening campaign from 2015 to 2018. the aim of the study is to analyse histological, clinical and radiological data collected during the screening campaign to build an ultrasound profile and a mammographic profile corresponding to brest cancers' different molecular sub-types (luminal a, luminal b, her2+, triple negative) using the bi-rads classification. the study has the following objectives: * to compare molecular profiles of breast cancers detected in a cohort of women diagnosed with tomosynthesis and ultrasound with molecular profiles of brest cancers detected in the cohort of women diagnosed with classical mammography and ultrasound * to describe molecular profiles of cancers detected only with ultrasound,


Eligibility criteria:
inclusion criteria: * women diagnosed with a breast cancer * detection of a breast cancer during the screening campaign organized between june 2015 and july 2018 in the following geographic zones : cantal, haute loire and puys de dôme exclusion criteria: * patients who expressed their opposition to the use of their personal data

Keywords: screening campaign molecular profile tomosynthesis ultrasound mammography
phase 1 trial of rp-3467 alone and in combination with olaparib in participants with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: this is a multicenter, open-label phase 1 trial to investigate the safety, pk, and pharmacodynamics of the polθ inhibitor rp-3467 alone or in combination with the poly-adp ribose polymerase inhibitor (parpi) olaparib in adults with molecularly selected advanced solid tumors.

this is a first-in-human phase 1, multi-center, open-label, dose-escalation study to: * evaluate the safety profile of rp-3467 when administered orally alone and in combination with olaparib and to define the mtd or mad for rp-3467 monotherapy and the rp2d for the combination * characterize the pk profile of rp-3467 alone and in combination with olaparib

Eligibility criteria:
inclusion criteria: * male or female participants ≥18 years of age at the time of signing the informed consent * eastern cooperative oncology group (ecog) performance status of 0 or 1 * participant must have one of the following that has progressed or was non-responsive to prior systemic therapy and for which no standard or available known therapeutic option exists: 1. locally advanced or metastatic epithelial ovarian cancer (including fallopian tube or primary peritoneal), or 2. metastatic breast cancer, or 3. metastatic castration-resistant prostate cancer (mcrpc), or 4. pancreatic adenocarcinoma * measurable disease per recist v1.1 (exceptions for participants with non-measurable but evaluable disease \[per recist and or psa/ca-125\]) * next generation sequencing (ngs) report demonstrating eligible tumor biomarker * provision of archival tumor tissue, or if adequate archival tumor tissue is not available, provision of a fresh biopsy if there is a lesion that can be safely biopsied * acceptable organ function at screening * acceptable hematologic function at screening * life expectancy ≥12 weeks after the start of the treatment according to the investigator's judgment exclusion criteria: * history or current condition, therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment. * uncontrolled, symptomatic brain metastases. * presence of other known active invasive cancers * history of myelodysplastic syndrome (mds) or acute myeloid leukemia (aml) diagnosis * prior therapy with a polθ inhibitor other than rp-3467
risk factors for community- and workplace transmission of covid-19

Conditions: Coronavirus

Summary: the project is an epidemiological observational study based on an electronic questionnaire on risk factors for covid-19 in the community and healthcare setting.

summary the data collected will identify real-life risk factors for getting the covid-19 diagnosis. the oslo university hospital/university of oslo web-based solution "nettskjema" will be used to collect data and consent forms. the impact of knowing the risk factors for covid-19 is tremendous because it can enable governments to conduct more targeted public health measurements than today to reduce the spread of the virus. detailed description research into an ongoing covid-19 outbreak is difficult because patients are isolated, and supplies of personal protective equipment (ppe) supplies are limited. the risk of transmission to study personal is non-negligible even when ppe is available. a study design based on an electronic questionnaire and consent from delivered from the oslo university hospital/university of oslo, gdpr (general data protection regulation) compliant "tsd" service has therefore been chosen. the study will be a case-control study based on a combined electronic consent form and questionnaire that the participants will fill in using a smartphone and electronic identification. the groups that will be included are: * hospitalized and non-hospitalized patients/persons with covid-19 at all stages of the disease and after the disease * hospitalized patients without covid-19 * healthcare personal or other groups with an increased risk of covid-19 * healthy volunteers participants may be followed with repeated questionnaires prospectively. biological samples biological samples may hold crucial information about the susceptibility to covid-19 and for susceptibility to the progression of the disease. it is within the scope of the study to analyze such samples from a limited number of participants which will be asked to provide such samples or hospitalized patients that have surplus material. the material will be analyzed with non-genetic methods most suitable to provide such information.

Eligibility criteria:
inclusion criteria: * norwegian adult exclusion criteria: * unable to consent